Pharmaceutical Technology35m
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
pharmaphorum46m
Roche ends the 30-year US hiatus in new stroke drugs
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...